Tranexamic Acid for Alloplastic Breast Reconstruction

Last updated: April 4, 2022
Sponsor: McMaster University
Overall Status: Active - Not Recruiting

Phase

3

Condition

Breast Cancer

Cancer

Treatment

N/A

Clinical Study ID

NCT04918589
13104
  • Ages 18-99
  • Female

Study Summary

Hematoma is a common complication of alloplastic breast reconstruction. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events.

In this randomized control trial (RCT) assessing TXA use in alloplastic breast reconstruction, one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in alloplastic breast reconstruction reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are 18 years or older;
  • Are undergoing one- or two-stage bilateral alloplastic breast reconstructionimmediately after bilateral mastectomy at either Hamilton Health Sciences or St.Joseph's Hospital Hamilton.

Exclusion

Exclusion Criteria:

  • Taking therapeutic anticoagulation;
  • Taking antiplatelet drugs;
  • Pregnant or breast feeding;
  • Allergic to TXA;
  • Cannot provide informed consent;
  • Alloplastic reconstruction is not performed immediately after mastectomy;
  • Have a documented coagulopathy or bleeding disorder, acquired disturbances of colourvision, subarachnoid hemorrhage, hematuria, irregular menstrual bleeding, or seizuredisorder.

Study Design

Total Participants: 106
Study Start date:
August 01, 2022
Estimated Completion Date:
August 31, 2024

Study Description

The primary objective of this study is to investigate the use of topical application of tranexamic Acid (TXA) to the surgical wound as a means to decrease hematoma formation compared to placebo in patients undergoing alloplastic breast reconstruction. This project is designed as a single-center RCT to evaluate the effectiveness of topical TXA in this patient population.

If enrolled in this study, patients individual breasts will be randomly assigned to one of two treatment groups for to apply to the wound before it is closed.

One breast will have an intravenous form of TXA applied topically to the surgical site. The other will be have a topical normal saline solution applied to the wound before closure (a placebo).

The patients will have the standard number of drains and postoperative instructions for breast reconstruction. They will follow-up at two weeks time in clinic for assessment, and emergency room visits will be also be evaluated. Standard of care will be practiced with respect to all procedures and visits.

Connect with a study center

  • Juravinski Hospital, Hamilton Health Sciences

    Hamilton, Ontario L8V 1C3
    Canada

    Site Not Available

  • St. Joseph's Healthcare, Charlton Campus

    Hamilton, Ontario L8N 4A6
    Canada

    Site Not Available

  • St. Joseph's Healthcare, King Campus

    Hamilton, Ontario L8G 5E4
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.